A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II α

被引:11
|
作者
Jensen, LH
Renodon-Cornière, A
Nitiss, KC
Hill, BT
Nitiss, JL
Jensen, PB
Sehested, M
机构
[1] Rigshosp, Lab Ctr, Dept Pathol, DK-2100 Copenhagen, Denmark
[2] Rigshosp, Finsen Ctr, Lab Expt Med Oncol, DK-2100 Copenhagen, Denmark
[3] St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38018 USA
[4] Ctr Rech Pierre Fabre, Div Cancerol, F-81100 Castres, France
关键词
topoisomerase II; epipodophyllotoxin; chemotherapy; DNA damage; surface plasmon resonance; mutation;
D O I
10.1016/S0006-2952(03)00342-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
F 11782 is a novel epipodophyllotoxin that targets eukaryotic topoisomerases and inhibits enzyme binding to DNA. While F 11782 has not been found to stabilize either topoisomerase I or topoisomerase II covalent complexes, drug treatment appears to result in DNA damage. F 11782 has also been shown to inhibit the DNA nucleotide excision repair (NER) pathway. Bisdioxopiperazine-resistant small cell lung cancer (SCLC) OC-NYH/Y165S and Chinese hamster ovary (CHO) CHO/159-1 cells having functional Y49F and Y165S mutations in the topoisomerase II alpha isoform were both resistant to F 11782. The catalytic activity of purified human Y50F and Y165S mutant topoisomerase 11 a (Y50F in the human protein corresponds to Y49F in the CHO protein) was likewise resistant to the inhibitory action of F 11782. F11782 was also found to induce a non-covalent salt-stable complex of human topoisomerase II with DNA that was ATP-independent. F 11782 thus displays a dual mechanism of action on human topoisomerase II alpha, reducing its affinity for DNA while also stabilizing the protein bound in the form of a salt-stable complex. Our results suggest that topoisomerase II alpha is a target of F 11782 in vivo, and that F 11782 may act as a novel topoisomerase II poison. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:623 / 631
页数:9
相关论文
共 50 条
  • [41] A two-drug model for etoposide action against human topoisomerase IIα
    Bromberg, KD
    Burgin, AB
    Osheroff, N
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (09) : 7406 - 7412
  • [42] Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors
    Mariana S. de Camargo
    Rone A. De Grandis
    Monize M. da Silva
    Patricia B. da Silva
    Mariana M. Santoni
    Carlos E. Eismann
    Amauri A. Menegário
    Marcia R. Cominetti
    Cleslei F. Zanelli
    Fernando R. Pavan
    Alzir A. Batista
    BioMetals, 2019, 32 : 89 - 100
  • [43] Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors
    de Camargo, Mariana S.
    De Grandis, Rone A.
    da Silva, Monize M.
    da Silva, Patricia B.
    Santoni, Mariana M.
    Eismann, Carlos E.
    Menegario, Amauri A.
    Cominetti, Marcia R.
    Zanelli, Cleslei F.
    Pavan, Fernando R.
    Batista, Alzir A.
    BIOMETALS, 2019, 32 (01) : 89 - 100
  • [44] Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent
    Lukka, Pradeep B.
    Chen, Ying Yi
    Finlay, Graeme J.
    Joseph, Wayne R.
    Richardson, Emma
    Paxton, James W.
    Baguley, Bruce C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (05) : 1013 - 1022
  • [45] Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent
    Pradeep B. Lukka
    Ying Yi Chen
    Graeme J. Finlay
    Wayne R. Joseph
    Emma Richardson
    James W. Paxton
    Bruce C. Baguley
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 1013 - 1022
  • [46] Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs
    Hashimoto, S
    Jing, YK
    Kawazoe, N
    Masuda, Y
    Nakajo, S
    Yoshida, T
    Kuroiwa, Y
    Nakaya, K
    LEUKEMIA RESEARCH, 1997, 21 (09) : 875 - 883
  • [47] The α4 residues of human DNA topoisomerase IIα function in enzymatic activity and anticancer drug sensitivity
    Suda, N
    Ito, Y
    Imai, T
    Kikumori, T
    Kikuchi, A
    Nishiyama, Y
    Yoshida, S
    Suzuki, M
    NUCLEIC ACIDS RESEARCH, 2004, 32 (05) : 1767 - 1773
  • [48] EXPERIMENTAL ANTITUMOUR ACTIVITY AND MECHANISM OF ACTION OF THE NOVEL ANTICANCER AGENT CCRG-81010
    WORKMAN, P
    LEE, FYF
    BRITISH JOURNAL OF CANCER, 1984, 50 (02) : 251 - 252
  • [49] Recent Advances in the Development of Catalytic Inhibitors of Human DNA Topoisomerase IIα As Novel Anticancer Agents
    Pogorelcnik, B.
    Perdih, A.
    Solmajer, T.
    CURRENT MEDICINAL CHEMISTRY, 2013, 20 (05) : 694 - 709
  • [50] Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies
    Arya, Girish Chandra
    Kaur, Kamalpreet
    Jaitak, Vikas
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 221